ClinicalTrials.gg
CompletedNCT04379869Updated Jul 9, 2021

To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers

A Phase 1 interventional study of NNZ-2591 and Placebo in Healthy Volunteers, sponsored by Neuren Pharmaceuticals Limited. Completed at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-09.

Sponsored by Neuren Pharmaceuticals Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of NNZ-2591 when administered to healthy volunteers.

Read the detailed description

This study is in two stages:

Stage 1: A First-in-Human (FIH), single dose escalation study of oral NNZ-2591 in healthy volunteers to establish safety, tolerability and pharmacokinetic parameters.

Stage 2: A First-in-Human (FIH), randomised, double-blind, placebo-controlled, Multiple Ascending Dose study (MAD) in healthy volunteers to establish safety, tolerability and pharmacokinetic parameters.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Neuren Pharmaceuticals Limited is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 55 years, inclusive;
  2. Weight at screening and admission between 45 kg and 100 kg;
  3. (BMI) between 18.0 and 32.0 kg/m2 inclusive;
  4. Healthy as determined by the Investigator based on pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead (ECG);
  5. Negative tests for surface antigen (HBsAg), virus antibody (anti-HCV) and (HIV)-1 and HIV-2 antibody at screening;
  6. Clinical laboratory test results up to >1.5 x Lower Limit of Normal (LLN) or \<1.5 x (ULN) at screening and admission and deemed not by the Investigator;
  7. Negative screen for alcohol and drugs of abuse at screening and admission;
  8. Non-smokers or ex-smokers (must have ceased smoking >3 months prior to screening visit);

    If female:

  9. Woman with no by reason of surgery or at least 1year post- menopause (i.e., 12 months post last menstrual period), and menopause confirmed by follicle-stimulating hormone (FSH) testing;
  10. If of childbearing potential, using an effective nonhormonal method of (intrauterine device; condom or occlusive cap [diaphragm or cervical or vault caps]; true abstinence; or vasectomized male partner (provided that he is the sole partner of that subject and had a vasectomy ≥30 days prior to screening) for the duration of the study and up to one month after the last medicinal product (IMP) administration;
  11. Negative serum pregnancy test at screening and negative urine pregnancy test on admission (women of childbearing potential only);

    If male:

  12. Using an effective method of contraception (condom) if sexually active with a female partner of child-bearing potential; true abstinence; or vasectomy ≥30 days prior to screening) throughout the study and for one month after the last IMP administration.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have a history as determined by the Investigator, or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders;
  2. Fridericia's correction factor for (QTcF) > 450 ms for male participants and >470ms for female participants or history of QT interval prolongation.
  3. Have a clinically relevant surgical history, as determined by the Investigator;
  4. Have a history of relevant atopy or drug ;
  5. Have a history of alcoholism or drug abuse;
  6. Consume more than 21 standard drinks a week for males and more than 14 standard drink if female [1 standard drink is any drink containing 10g of alcohol, regardless of container size or alcohol type].
  7. Have a significant infection or known inflammatory process on screening or admission;
  8. Have acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) at the time of screening or admission;
  9. Have used any prescription or non-prescription medicines within 2 weeks of admission, unless in the investigator's opinion will not affect determination of safety or other study assessments. Occasional paracetamol use (up to 2g/day is permitted);
  10. Have received any drug within 30 days prior to screening;
  11. Have used tobacco or nicotine products within 3 months of screening
  12. Have donated or received any blood or blood products within the 3 months prior to screening;
  13. Cannot communicate reliably with the investigator;
  14. Are unlikely to co-operate with the requirements of the study;
  15. Are unwilling or unable to give written .

    If female:

  16. Pregnancy or breast-feeding;
  17. Woman of not willing to use an accepted effective method or using hormonal contraceptives;

    If male:

  18. Not willing to use an accepted effective method of contraception.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    NNZ-2591 Single dose Cohort 1

    Single dose of oral NNZ-2591 in healthy volunteers

    Drug: NNZ-2591

  • Experimental
    NNZ-2591 Single dose Cohort 2

    Single dose of oral NNZ-2591 in healthy volunteers

    Drug: NNZ-2591

  • Experimental
    NNZ-2591 MAD Cohort 1

    Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers

    Drug: NNZ-2591 · Drug: Placebo

  • Experimental
    NNZ-2591 MAD Cohort 2

    Multiple Ascending Dose (MAD) of oral NNZ-2591 in healthy volunteers

    Drug: NNZ-2591 · Drug: Placebo

Interventions

  • Single dose of NNZ-2591

  • DrugPlacebo

    Comparator for double-blind MAD

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability measured through Adverse Events /Serious Adverse Events

    The frequency and severity of Adverse Events in healthy volunteers administered single and repeated oral doses of NNZ-2591

    Time frame: 25 days

Secondary outcomes

  1. Pharmacokinetic - Cmax

    Maximum observed plasma concentration (Cmax) of NNZ-2591

    Time frame: 17 days

  2. Pharmacokinetic - AUC∞

    Area under the concentration-time curve from time 0 to infinity of NNZ-2591

    Time frame: 17 days

  3. Pharmacokinetic - Tmax

    Time to Cmax of NNZ-2591

    Time frame: 17 days

  4. Pharmacokinetic - t1/2

    Terminal elimination half-life

    Time frame: 17 days

07

Study locations

2 sites
  • Scientia Clinical Research
    Sydney, New South Wales 2031, Australia
  • Linear Clinical Research, The Queen Elizabeth II Medical Centre
    Nedlands, Western Australia 6009, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Feb 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2020
First posted
May 8, 2020
StartActual
May 29, 2020
Primary completionActual
Feb 11, 2021
CompletionActual
Feb 11, 2021
Last update
Jul 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04379869
Lead sponsor
Neuren Pharmaceuticals Limited
Responsible party
Sponsor
First posted
May 8, 2020
Start date
May 29, 2020
Primary completion
Feb 11, 2021
Completion
Feb 11, 2021
Last update
Jul 9, 2021

Study contacts

James Shaw
study director · Neuren Pharmaceuticals
Jasmine Williams
principal investigator · Linear Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ercanetide

Start the discussion